Browsing by Author "Medić, Branislava (56029608400)"
Now showing 1 - 6 of 6
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Correlation of Ionized Magnesium with the Parameters of Oxidative Stress as Potential Biomarkers in Patients with Anxiety and Depression: A Pilot Study(2022) ;Opanković, Ana (57443015600) ;Milovanović, Srđan (25621995600) ;Radosavljević, Branimir (56355246100) ;Čavić, Milena (39760938900) ;Besu Žižak, Irina (34567735200) ;Bukumirić, Zoran (36600111200) ;Latas, Milan (6507748007) ;Medić, Branislava (56029608400) ;Vučković, Sonja (7003869333) ;Srebro, Dragana (55601466500)Savić Vujović, Katarina (57217857650)Background: Magnesium (Mg) is the second most abundant intracellular cation. Ionized Mg is the only active form of Mg. The concentration of ionized Mg could be a potentially novel biomarker for anxiety and depression. Aim: The aim of this study was to assess the serum concentration of ionized Mg and its correlation with biomarkers of oxidative stress and inflammation in patients with anxiety and depression. Methods: In this study included 93 respondents were divided into 3 groups: C (control group—18 respondents); A (patients with anxiety disorder, dissociative/conversion disorders and somatoform disorders—36 patients); D (patients with depression—39 patients). Clinical diagnosis was based on ICD-10 criteria. Blood samples were used for standard laboratory analysis, ionized Mg analysis, oxidative stress, and inflammatory parameters. Results: Statistical significance was recorded between healthy volunteers and patients (anxiety/depression) in ionized Mg values. In anxious patients, malondialdehyde (MDA) had a positive correlation between the parameters of oxidative stress with ionized Mg. In depressive patients, MDA had a positive correlation, and glutathione peroxidase 1 (GPX1) a negative correlation with the concentration of ionized Mg. Conclusion: Ionized Mg and its correlation with parameters of oxidative stress could be potential biomarkers in anxious and depressive patients. © The Author(s) 2022. - Some of the metrics are blocked by yourconsent settings
Publication Correlation of Ionized Magnesium with the Parameters of Oxidative Stress as Potential Biomarkers in Patients with Anxiety and Depression: A Pilot Study(2022) ;Opanković, Ana (57443015600) ;Milovanović, Srđan (25621995600) ;Radosavljević, Branimir (56355246100) ;Čavić, Milena (39760938900) ;Besu Žižak, Irina (34567735200) ;Bukumirić, Zoran (36600111200) ;Latas, Milan (6507748007) ;Medić, Branislava (56029608400) ;Vučković, Sonja (7003869333) ;Srebro, Dragana (55601466500)Savić Vujović, Katarina (57217857650)Background: Magnesium (Mg) is the second most abundant intracellular cation. Ionized Mg is the only active form of Mg. The concentration of ionized Mg could be a potentially novel biomarker for anxiety and depression. Aim: The aim of this study was to assess the serum concentration of ionized Mg and its correlation with biomarkers of oxidative stress and inflammation in patients with anxiety and depression. Methods: In this study included 93 respondents were divided into 3 groups: C (control group—18 respondents); A (patients with anxiety disorder, dissociative/conversion disorders and somatoform disorders—36 patients); D (patients with depression—39 patients). Clinical diagnosis was based on ICD-10 criteria. Blood samples were used for standard laboratory analysis, ionized Mg analysis, oxidative stress, and inflammatory parameters. Results: Statistical significance was recorded between healthy volunteers and patients (anxiety/depression) in ionized Mg values. In anxious patients, malondialdehyde (MDA) had a positive correlation between the parameters of oxidative stress with ionized Mg. In depressive patients, MDA had a positive correlation, and glutathione peroxidase 1 (GPX1) a negative correlation with the concentration of ionized Mg. Conclusion: Ionized Mg and its correlation with parameters of oxidative stress could be potential biomarkers in anxious and depressive patients. © The Author(s) 2022. - Some of the metrics are blocked by yourconsent settings
Publication Pain Management After Surgical Tonsillectomy: Is There a Favorable Analgesic?(2019) ;Jotić, Ana (35173257500) ;Savić Vujović, Katarina (56362541300) ;Milovanović, Jovica (6603250148) ;Vujović, Aleksandar (57190496164) ;Radin, Zorana (57208752128) ;Milić, Nataša (7003460927) ;Vučković, Sonja (7003869333) ;Medić, Branislava (56029608400)Prostran, Milica (7004009031)The aim of this study was to examine how ibuprofen and paracetamol prevent pain after cold-steel extracapsular tonsillectomy in children. Also, we examined the relation between age, gender, nausea, postoperative bleeding, antibiotic use, type of diet, and postoperative pain intensity and the type of administered analgesic. A prospective study was conducted on 147 children (95 males and 52 females, aged 7-17 years) who underwent tonsillectomy in the Clinical-Hospital Center “Dragiša Mišović” from January 1 to June 30, 2016. The degree of pain was measured using a visual analog scale (VAS). We did not observe any significant differences in postoperative nausea, hospitalization rate postoperative bleeding, and antibiotic use between the paracetamol and ibuprofen groups. A test of within-patient effects showed that VAS scores changed significantly during the postoperative follow-up period (P =.00), but there were no significant differences between the groups (P =.778). After 12 hours, 29.3% of the patients on paracetamol and 21.8% on ibuprofen were transferred to a soft diet; after 24 hours, 84.8% of the paracetamol group and 85.5% of the ibuprofen group were on a soft diet (χ2 test, P <.05). There was a statistically significant correlation between VAS scores measured 4 hours after the surgery and the time of transference to the soft diet (Spearman ρ test, P <.001). The transfer to soft and normal diets was not significantly different between the 2 groups as assessed by the VAS scores (Pearson χ2 test, P =.565).There is still no consensus on the most effective postoperative pain-control regiment after tonsillectomy. This study showed that satisfactory pain management was achieved equally with both paracetamol and ibuprofen. © The Author(s) 2019. - Some of the metrics are blocked by yourconsent settings
Publication The attitudes of medical students towards rare diseases: A cross-sectional study; [Stavovi studenata medicine o retkim bolestima: Studija preseka](2016) ;Medić, Branislava (56029608400) ;Divac, Nevena (23003936900) ;Stopić, Bojan (57190427195) ;Vujović, Katarina Savić (56362541300) ;Glišić, Andreja (56571537500) ;Cerovac, Nataša (23476572500) ;Stojanović, Radan (7003903083) ;Srebro, Dragana (55601466500)Prostran, Milica (7004009031)Background/Aim. Rare diseases are chronic, degenerative and may lead to permanent disability. We aimed to assess knowledge and attitudes of the 3rd and 6th year medical students towards the treatment of rare diseases in Serbia. Methods. In this cross-sectional study, two samples of students were questioned for a survey: 350/446 (78.48%) students of the 3rd year, and 242/517 (46.81%) students of the 6th year. Results. Sixth year students estimated that they were more informed on the issue analyzed than the 3rd year students (median value of 4 and 3, interquartile range of 3–5, and 1–4, respectively; p < 0.05). However, a significant percentage of participants esti-mated incorrectly the prevalence of rare diseases according to the European Union standards (3rd year – 42.68%, 6th year - 49.55%). Core curriculum subjects were the main source of in-formation on rare diseases (3rd year – 63.14%; 6th year – 92.14%). Our participants agreed that the most important problems are the following: high drug prices, difficult access to drugs and lack of public information. Students found, without any differences, that community access to effective drugs for rare disease should be improved (median value – 10, interquar-tile range 8–10 in both groups, p < 0.05). In order to improve pharmacotherapy of rare diseases in Serbia, the participants suggested establishment of a National Plan for Rare Diseases, approval of more appropriate drugs, simplified access to appropriate medicines, and more rapid diagnostics. Conclusion. It is necessary to improve the knowledge and attitudes of medical students towards pharmacotherapy of rare diseases. © 2016, Institut za Vojnomedicinske Naucne Informacije/Documentaciju. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's Disease(2016) ;Divac, Nevena (23003936900) ;Stojanović, Radan (7003903083) ;Savić Vujović, Katarina (56362541300) ;Medić, Branislava (56029608400) ;Damjanović, Aleksandar (7004519596)Prostran, Milica (7004009031)Psychotic symptoms are present in up to 50% of patients with Parkinson's disease. These symptoms have detrimental effects on patients' and caregivers' quality of life and may predict mortality. The pathogenesis of psychotic symptoms in Parkinson's disease is complex, but the use of dopaminergic medications is one of the risk factors. The treatment of psychotic symptoms in Parkinson's disease is complicated due to the ability of antipsychotic medications to worsen motor symptoms. The efficacy of clozapine in the treatment of psychosis in patients with Parkinson's disease has been confirmed in several clinical trials; however, the adverse effects and the necessity of blood count monitoring are the reasons why the use of this drug is challenging. The studies on safety and efficacy of other antipsychotics conflicting results. The use of antipsychotics in these patients is also associated with increased mortality. Psychotic symptoms in Parkinson's disease per se are also proven predictors of mortality. Thus it is necessary to treat psychotic symptoms but the choice of an antipsychotic should be based on careful risk/benefit assessment. Pimavanserin as a novel therapeutic option with more favorable adverse effects profile is now available for this indication, but careful postmarketing monitoring is necessary to establish the true picture of this drug's long-term safety and efficacy. © 2016 Nevena Divac et al. - Some of the metrics are blocked by yourconsent settings
Publication The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's Disease(2016) ;Divac, Nevena (23003936900) ;Stojanović, Radan (7003903083) ;Savić Vujović, Katarina (56362541300) ;Medić, Branislava (56029608400) ;Damjanović, Aleksandar (7004519596)Prostran, Milica (7004009031)Psychotic symptoms are present in up to 50% of patients with Parkinson's disease. These symptoms have detrimental effects on patients' and caregivers' quality of life and may predict mortality. The pathogenesis of psychotic symptoms in Parkinson's disease is complex, but the use of dopaminergic medications is one of the risk factors. The treatment of psychotic symptoms in Parkinson's disease is complicated due to the ability of antipsychotic medications to worsen motor symptoms. The efficacy of clozapine in the treatment of psychosis in patients with Parkinson's disease has been confirmed in several clinical trials; however, the adverse effects and the necessity of blood count monitoring are the reasons why the use of this drug is challenging. The studies on safety and efficacy of other antipsychotics conflicting results. The use of antipsychotics in these patients is also associated with increased mortality. Psychotic symptoms in Parkinson's disease per se are also proven predictors of mortality. Thus it is necessary to treat psychotic symptoms but the choice of an antipsychotic should be based on careful risk/benefit assessment. Pimavanserin as a novel therapeutic option with more favorable adverse effects profile is now available for this indication, but careful postmarketing monitoring is necessary to establish the true picture of this drug's long-term safety and efficacy. © 2016 Nevena Divac et al.
